

Rosacea - Pipeline Review, H1 2020

<https://marketpublishers.com/r/RDF0DC61C2DEN.html>

Date: April 2020

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: RDF0DC61C2DEN

Abstracts

Rosacea - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H1 2020, provides an overview of the Rosacea (Dermatology) pipeline landscape.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 10, 5 and 7 respectively.

Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).

The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Rosacea - Overview
- Rosacea - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Rosacea - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Rosacea - Companies Involved in Therapeutics Development
- Accutis Pharmaceuticals Inc
- Afecta Pharmaceuticals Inc
- Aiviva BioPharma Inc
- AlfaSigma SpA
- AOBiome LLC
- Biomimetix JV LLC
- BioPharmX Inc
- Botanix Pharmaceuticals Ltd
- Cellix Bio Pvt Ltd
- Cutanea Life Sciences Inc
- Dermata Therapeutics LLC
- ELORAC Inc
- Emeriti Pharma AB
- GlycoMira Therapeutics Inc
- Hovione FarmaCiencia SA
- Maruho Co Ltd
- Matrisys Bioscience Inc
- Menlo Therapeutics Inc
- Sol-Gel Technologies Ltd
- Sunny Pharmtech Inc
- Tarsus Pharmaceuticals Inc
- TWi Biotechnology Inc
- Rosacea - Drug Profiles
- AC-701 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
ACUD-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AFX-4031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AIV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benzoyl peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMX-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPX-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTX-1702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carbamide peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

CLX-1621 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLXDER-621 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLXDER-622 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLXDER-623 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

doxycycline hyclate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-0003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FMX-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HY-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-1220 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omiganan pentahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylbutyrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rifaximin DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rosacea - Dormant Projects

Rosacea - Discontinued Products

Rosacea - Product Development Milestones

Featured News & Press Releases

Feb 18, 2020: Foamix announces integrated efficacy results from the FMX103 1.5% Topical Minocycline Foam Phase 3 program for Rosacea

Feb 13, 2020: Sol-Gel announces positive topline results from open-label, long-term safety study of Epsolay for treatment up to 52 Weeks

Feb 06, 2020: Foamix announces publication of Phase 3 Studies evaluating FMX103 for the treatment of papulopustular rosacea in Journal of the American Academy of Dermatology

Jan 21, 2020: Sol-Gel announces presentation Epsolay at the 16th Annual Maui Derm for Dermatologists 2020 Meeting

Dec 09, 2019: Botanix initiates BTX 1702 rosacea study

Oct 23, 2019: Foamix enters into manufacturing and supply agreement For FMX103

Oct 17, 2019: Foamix announces FDA acceptance of its New Drug Application for FMX103 Minocycline foam for the treatment of Moderate-to-Severe Papulopustular Rosacea

Oct 16, 2019: Sol-Gel to present on potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference

Oct 10, 2019: Foamix to present data on FMX-103 at 39th Annual Fall Clinical Dermatology Conference

Sep 20, 2019: Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel

Aug 06, 2019: Foamix seeks FDA approval for FMX103 to treat rosacea

Jul 08, 2019: Sol-Gel announces positive top-line results from epsolay phase 3 program in papulopustular Rosacea

Jun 26, 2019: BioPharmX reports positive results from BPX-041 trial for rosacea

May 22, 2019: BioPharmX announces last patient visit in Phase 2b trial of BPX-04 for papulopustular rosacea

Mar 04, 2019: BioPharmX completes enrollment in phase 2b trial of BPX-04 for patients with papulopustular rosacea

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Rosacea, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Rosacea - Pipeline by Accutis Pharmaceuticals Inc, H1 2020
Rosacea - Pipeline by Afecta Pharmaceuticals Inc, H1 2020
Rosacea - Pipeline by Aiviva BioPharma Inc, H1 2020
Rosacea - Pipeline by AlfaSigma SpA, H1 2020
Rosacea - Pipeline by AOBiome LLC, H1 2020
Rosacea - Pipeline by Biomimetix JV LLC, H1 2020
Rosacea - Pipeline by BioPharmX Inc, H1 2020
Rosacea - Pipeline by Botanix Pharmaceuticals Ltd, H1 2020
Rosacea - Pipeline by Cellix Bio Pvt Ltd, H1 2020
Rosacea - Pipeline by Cutanea Life Sciences Inc, H1 2020
Rosacea - Pipeline by Dermata Therapeutics LLC, H1 2020
Rosacea - Pipeline by ELORAC Inc, H1 2020
Rosacea - Pipeline by Emeriti Pharma AB, H1 2020
Rosacea - Pipeline by GlycoMira Therapeutics Inc, H1 2020
Rosacea - Pipeline by Hovione FarmaCiencia SA, H1 2020
Rosacea - Pipeline by Maruho Co Ltd, H1 2020
Rosacea - Pipeline by Matrisys Bioscience Inc, H1 2020
Rosacea - Pipeline by Menlo Therapeutics Inc, H1 2020
Rosacea - Pipeline by Sol-Gel Technologies Ltd, H1 2020
Rosacea - Pipeline by Sunny Pharmtech Inc, H1 2020
Rosacea - Pipeline by Tarsus Pharmaceuticals Inc, H1 2020
Rosacea - Pipeline by TWi Biotechnology Inc, H1 2020
Rosacea - Dormant Projects, H1 2020
Rosacea - Dormant Projects, H1 2020 (Contd..1), H1 2020
Rosacea - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Rosacea, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Accutis Pharmaceuticals Inc
Afecta Pharmaceuticals Inc
Aiviva BioPharma Inc
AlfaSigma SpA
AOBiome LLC
Biomimetix JV LLC
BioPharmX Inc
Botanix Pharmaceuticals Ltd
Cellix Bio Pvt Ltd
Cutanea Life Sciences Inc
Dermata Therapeutics LLC
ELORAC Inc
Emeriti Pharma AB
GlycoMira Therapeutics Inc
Hovione FarmaCiencia SA
Maruho Co Ltd
Matrisys Bioscience Inc
Menlo Therapeutics Inc
Sol-Gel Technologies Ltd
Sunny Pharmtech Inc
Tarsus Pharmaceuticals Inc
TWi Biotechnology Inc

I would like to order

Product name: Rosacea - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/RDF0DC61C2DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RDF0DC61C2DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970